Compare Adaptive Biotechnologies Corp (ADPT) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Symbotic Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Symbotic Inc trades at $40.45 (market cap $5.26B). The key difference: Symbotic Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SYM | |
|---|---|---|
Market Cap | $3.33B | $5.26B |
Sector | Health | Technology |
52-Week High | $22.37 | $87.30 |
52-Week Low | $10.24 | $38.57 |
Enterprise Value | $3.19B | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SYM trades at $44.46, up 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $2.25B in 2025. Recent news highlights the acquisition of ARMS Innovations, expanding its warehouse automation solutions, amid high investor interest in robotics stocks.
The outlook is cautiously optimistic with a consensus price target of $57.50, but risks include negative net income margins and high valuation multiples like EV/EBITDA of 246.96. Upside potential hinges on execution in the growing automation market, while downside risks involve competitive pressures and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
